Alvotech has pushed its second biosimilar into Phase III clinical study development, the Icelandic firm’s AVT04 ustekinumab product referencing Janssen’s $7.7bn Stelara treatment for autoimmune diseases.
The first patient has been dosed in the firm’s AVT04-GL-301 comparative study, which aims to demonstrate therapeutic equivalence with Stelara...






